Botulism Immune Globulin IV (Intravenous-Human)
- Atc Codes:J06AA04
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: BabyBIG.
Drug combinations
Chemistry
Pharmacologic Category
Serums, Toxoids, and Vaccines; Serums; Immune Globulin. (ATC-Code: J06AA04).
Mechanism of action
Botulism immune globulin IV (BIG-IV), an immunoglobulin G (IgG) prepared from plasma of adults immunized with pentavalent botulinum toxoid, neutralizes botulinum toxin types A and B.
Therapeutic use
Treatment of infant botulism caused by toxin type A or B in patients <1 year of age.
Pregnancy and lactiation implications
Reproduction studies not conducted.
Unlabeled use
Contraindications
Hypersensitivity to human immune globulin preparations or any component of the formulation. Selective immunoglobulin A deficiency.
Warnings and precautions
Hypersensitivity and anaphylactic reactions may occur. Aseptic meningitis syndrome reported with intravenous immune globulin administration (rare). Acute renal dysfunction (increased serum creatinine, oliguria, acute renal failure) can rarely occur. Not indicated for use in adults. Not indicated for children ≥1 year of age. As a product of human plasma it may potentially contain infectious agents which could transmit disease (risk of Creutzfeldt-Jakob disease). For I.V. administration exclusively. May facilitate oral candidiasis. Irritability is common. May cause agitation. Rash is common (be mindful if patient is also receiving lamotrigine). Gastrointestinal side-effects are common. Concomitant use with SSRIs, lithium, or valproic acid may produce additive effects. If hypotension or anaphylaxis occurs, BIG-IV should be discontinued immediately.